Stem definition | Drug id | CAS RN |
---|---|---|
nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives | 770 | 147-94-4 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 11.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 20 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.67 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 41.67 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.87 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.17 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 17, 1969 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 3463.17 | 63.34 | 784 | 5105 | 10098 | 2342098 |
Neutropenia | 1071.51 | 63.34 | 364 | 5525 | 21184 | 2331012 |
Febrile bone marrow aplasia | 971.04 | 63.34 | 179 | 5710 | 678 | 2351518 |
Sepsis | 960.36 | 63.34 | 323 | 5566 | 18165 | 2334031 |
Pyrexia | 952.98 | 63.34 | 429 | 5460 | 53279 | 2298917 |
Thrombocytopenia | 836.46 | 63.34 | 294 | 5595 | 18837 | 2333359 |
Septic shock | 732.66 | 63.34 | 210 | 5679 | 6844 | 2345352 |
Pancytopenia | 725.87 | 63.34 | 233 | 5656 | 11219 | 2340977 |
Bone marrow failure | 679.67 | 63.34 | 189 | 5700 | 5497 | 2346699 |
Mucosal inflammation | 644.31 | 63.34 | 178 | 5711 | 5046 | 2347150 |
Pneumonia | 553.61 | 63.34 | 289 | 5600 | 49007 | 2303189 |
Acute myeloid leukaemia | 514.13 | 63.34 | 130 | 5759 | 2580 | 2349616 |
Venoocclusive liver disease | 493.29 | 63.34 | 96 | 5793 | 512 | 2351684 |
Multiple organ dysfunction syndrome | 465.05 | 63.34 | 151 | 5738 | 7490 | 2344706 |
Haematotoxicity | 464.02 | 63.34 | 102 | 5787 | 1065 | 2351131 |
Hypotension | 441.60 | 63.34 | 217 | 5672 | 32219 | 2319977 |
Colitis | 416.74 | 63.34 | 127 | 5762 | 5099 | 2347097 |
Posterior reversible encephalopathy syndrome | 411.70 | 63.34 | 107 | 5782 | 2373 | 2349823 |
Respiratory failure | 391.31 | 63.34 | 154 | 5735 | 13374 | 2338822 |
Product use in unapproved indication | 364.69 | 63.34 | 139 | 5750 | 11061 | 2341135 |
Pleural effusion | 344.95 | 63.34 | 135 | 5754 | 11533 | 2340663 |
Platelet count decreased | 338.01 | 63.34 | 145 | 5744 | 15668 | 2336528 |
Blood culture positive | 328.74 | 63.34 | 71 | 5818 | 676 | 2351520 |
Alanine aminotransferase increased | 307.49 | 63.34 | 131 | 5758 | 13901 | 2338295 |
Neutropenic colitis | 302.48 | 63.34 | 57 | 5832 | 247 | 2351949 |
Acute lymphocytic leukaemia recurrent | 292.84 | 63.34 | 53 | 5836 | 174 | 2352022 |
Bronchopulmonary aspergillosis | 281.33 | 63.34 | 66 | 5823 | 938 | 2351258 |
Acute kidney injury | 280.73 | 63.34 | 153 | 5736 | 27969 | 2324227 |
Vomiting | 280.59 | 63.34 | 216 | 5673 | 71386 | 2280810 |
Hypofibrinogenaemia | 280.30 | 63.34 | 48 | 5841 | 102 | 2352094 |
Neurotoxicity | 277.91 | 63.34 | 76 | 5813 | 2054 | 2350142 |
Myelodysplastic syndrome | 277.55 | 63.34 | 79 | 5810 | 2481 | 2349715 |
Neoplasm recurrence | 277.45 | 63.34 | 56 | 5833 | 369 | 2351827 |
Tumour lysis syndrome | 271.66 | 63.34 | 65 | 5824 | 1010 | 2351186 |
Bacteraemia | 269.45 | 63.34 | 71 | 5818 | 1659 | 2350537 |
Seizure | 260.55 | 63.34 | 139 | 5750 | 24327 | 2327869 |
Acute myeloid leukaemia recurrent | 251.64 | 63.34 | 46 | 5843 | 162 | 2352034 |
Diarrhoea | 239.01 | 63.34 | 210 | 5679 | 83354 | 2268842 |
Nausea | 238.66 | 63.34 | 239 | 5650 | 111950 | 2240246 |
Hypoxia | 230.52 | 63.34 | 85 | 5804 | 6142 | 2346054 |
Tachycardia | 229.14 | 63.34 | 112 | 5777 | 16297 | 2335899 |
Hypokalaemia | 221.79 | 63.34 | 96 | 5793 | 10558 | 2341638 |
Blood bilirubin increased | 220.34 | 63.34 | 79 | 5810 | 5266 | 2346930 |
Haemophagocytic lymphohistiocytosis | 216.49 | 63.34 | 57 | 5832 | 1326 | 2350870 |
Neutrophil count decreased | 215.25 | 63.34 | 82 | 5807 | 6485 | 2345711 |
Off label use | 214.33 | 63.34 | 187 | 5702 | 73411 | 2278785 |
Neutropenic sepsis | 209.38 | 63.34 | 56 | 5833 | 1386 | 2350810 |
Acute respiratory distress syndrome | 207.82 | 63.34 | 67 | 5822 | 3225 | 2348971 |
Bacterial infection | 202.81 | 63.34 | 60 | 5829 | 2161 | 2350035 |
Aplasia | 201.40 | 63.34 | 44 | 5845 | 443 | 2351753 |
Disease progression | 198.49 | 63.34 | 103 | 5786 | 16992 | 2335204 |
Abdominal pain | 194.56 | 63.34 | 130 | 5759 | 34244 | 2317952 |
Hyperbilirubinaemia | 191.50 | 63.34 | 53 | 5836 | 1496 | 2350700 |
Venoocclusive disease | 190.99 | 63.34 | 38 | 5851 | 230 | 2351966 |
Clostridium difficile colitis | 189.11 | 63.34 | 56 | 5833 | 2023 | 2350173 |
Infection | 187.69 | 63.34 | 101 | 5788 | 17928 | 2334268 |
Enterococcal infection | 187.59 | 63.34 | 45 | 5844 | 706 | 2351490 |
Cytomegalovirus infection | 186.81 | 63.34 | 59 | 5830 | 2654 | 2349542 |
Hypoalbuminaemia | 182.99 | 63.34 | 50 | 5839 | 1344 | 2350852 |
Encephalopathy | 182.65 | 63.34 | 66 | 5823 | 4495 | 2347701 |
Respiratory distress | 182.39 | 63.34 | 68 | 5821 | 5061 | 2347135 |
Pulmonary oedema | 182.02 | 63.34 | 75 | 5814 | 7288 | 2344908 |
Aspartate aminotransferase increased | 181.72 | 63.34 | 88 | 5801 | 12524 | 2339672 |
Fungaemia | 180.22 | 63.34 | 36 | 5853 | 223 | 2351973 |
Second primary malignancy | 179.41 | 63.34 | 46 | 5843 | 960 | 2351236 |
Anaemia | 176.49 | 63.34 | 123 | 5766 | 34669 | 2317527 |
Leukaemia recurrent | 175.18 | 63.34 | 35 | 5854 | 217 | 2351979 |
Ascites | 172.78 | 63.34 | 67 | 5822 | 5553 | 2346643 |
Renal failure | 171.69 | 63.34 | 94 | 5795 | 17255 | 2334941 |
Pulmonary haemorrhage | 170.42 | 63.34 | 46 | 5843 | 1179 | 2351017 |
Leukopenia | 167.85 | 63.34 | 78 | 5811 | 10118 | 2342078 |
Graft versus host disease | 162.00 | 63.34 | 42 | 5847 | 917 | 2351279 |
Myelopathy | 160.67 | 63.34 | 35 | 5854 | 347 | 2351849 |
Staphylococcal sepsis | 157.63 | 63.34 | 42 | 5847 | 1023 | 2351173 |
Aspergillus infection | 156.99 | 63.34 | 41 | 5848 | 922 | 2351274 |
Device related infection | 156.54 | 63.34 | 54 | 5835 | 3205 | 2348991 |
Hepatocellular injury | 148.68 | 63.34 | 55 | 5834 | 4000 | 2348196 |
White blood cell count decreased | 148.65 | 63.34 | 87 | 5802 | 18121 | 2334075 |
Fungal infection | 145.71 | 63.34 | 57 | 5832 | 4832 | 2347364 |
Enterococcal bacteraemia | 141.40 | 63.34 | 27 | 5862 | 127 | 2352069 |
Cytopenia | 140.87 | 63.34 | 38 | 5851 | 971 | 2351225 |
Leukoencephalopathy | 139.49 | 63.34 | 36 | 5853 | 771 | 2351425 |
Haemoglobin decreased | 133.24 | 63.34 | 81 | 5808 | 18070 | 2334126 |
Disseminated intravascular coagulation | 132.30 | 63.34 | 48 | 5841 | 3302 | 2348894 |
Headache | 131.06 | 63.34 | 149 | 5740 | 80030 | 2272166 |
Disease recurrence | 130.91 | 63.34 | 48 | 5841 | 3403 | 2348793 |
Staphylococcal infection | 130.72 | 63.34 | 54 | 5835 | 5272 | 2346924 |
Mucormycosis | 130.62 | 63.34 | 30 | 5859 | 385 | 2351811 |
Ejection fraction decreased | 129.06 | 63.34 | 45 | 5844 | 2756 | 2349440 |
Mental status changes | 128.27 | 63.34 | 54 | 5835 | 5528 | 2346668 |
Hypertriglyceridaemia | 126.28 | 63.34 | 34 | 5855 | 862 | 2351334 |
Stomatitis | 125.62 | 63.34 | 63 | 5826 | 9647 | 2342549 |
Hepatotoxicity | 123.15 | 63.34 | 46 | 5843 | 3435 | 2348761 |
Neuropathy peripheral | 118.71 | 63.34 | 64 | 5825 | 11368 | 2340828 |
Escherichia bacteraemia | 113.61 | 63.34 | 26 | 5863 | 328 | 2351868 |
Neutropenic infection | 112.19 | 63.34 | 23 | 5866 | 165 | 2352031 |
Decreased appetite | 112.12 | 63.34 | 87 | 5802 | 28804 | 2323392 |
Clostridium test positive | 111.81 | 63.34 | 25 | 5864 | 282 | 2351914 |
Rhinovirus infection | 111.48 | 63.34 | 25 | 5864 | 286 | 2351910 |
Acute lymphocytic leukaemia | 110.26 | 63.34 | 27 | 5862 | 463 | 2351733 |
Fluid overload | 110.03 | 63.34 | 40 | 5849 | 2766 | 2349430 |
Cerebral haemorrhage | 109.21 | 63.34 | 48 | 5841 | 5456 | 2346740 |
Left ventricular dysfunction | 106.65 | 63.34 | 32 | 5857 | 1208 | 2350988 |
Cardiotoxicity | 106.47 | 63.34 | 32 | 5857 | 1215 | 2350981 |
Hemiparesis | 105.52 | 63.34 | 41 | 5848 | 3409 | 2348787 |
Cardiac failure | 104.50 | 63.34 | 60 | 5829 | 12034 | 2340162 |
Malignant neoplasm progression | 104.34 | 63.34 | 60 | 5829 | 12068 | 2340128 |
Candida infection | 101.74 | 63.34 | 38 | 5851 | 2835 | 2349361 |
Unresponsive to stimuli | 101.54 | 63.34 | 44 | 5845 | 4832 | 2347364 |
Palmar-plantar erythrodysaesthesia syndrome | 101.06 | 63.34 | 42 | 5847 | 4159 | 2348037 |
Pseudomonas infection | 99.89 | 63.34 | 30 | 5859 | 1136 | 2351060 |
Acute respiratory failure | 99.68 | 63.34 | 38 | 5851 | 3000 | 2349196 |
Cystitis haemorrhagic | 98.47 | 63.34 | 26 | 5863 | 610 | 2351586 |
Hyperglycaemia | 98.20 | 63.34 | 43 | 5846 | 4842 | 2347354 |
Herpes simplex | 98.13 | 63.34 | 29 | 5860 | 1038 | 2351158 |
Transaminases increased | 97.50 | 63.34 | 42 | 5847 | 4545 | 2347651 |
Human herpesvirus 6 infection | 96.07 | 63.34 | 23 | 5866 | 357 | 2351839 |
Cardiac arrest | 95.30 | 63.34 | 61 | 5828 | 14869 | 2337327 |
Staphylococcal bacteraemia | 94.79 | 63.34 | 25 | 5864 | 584 | 2351612 |
Neoplasm progression | 93.54 | 63.34 | 41 | 5848 | 4627 | 2347569 |
Muscular weakness | 92.95 | 63.34 | 60 | 5829 | 14837 | 2337359 |
Enterobacter infection | 92.64 | 63.34 | 21 | 5868 | 253 | 2351943 |
Hypertension | 92.47 | 63.34 | 76 | 5813 | 27285 | 2324911 |
Progressive multifocal leukoencephalopathy | 92.22 | 63.34 | 33 | 5856 | 2179 | 2350017 |
Enterocolitis | 91.31 | 63.34 | 26 | 5863 | 814 | 2351382 |
Hepatomegaly | 90.83 | 63.34 | 31 | 5858 | 1778 | 2350418 |
Chills | 90.59 | 63.34 | 60 | 5829 | 15492 | 2336704 |
Drug interaction | 90.28 | 63.34 | 77 | 5812 | 29086 | 2323110 |
Hepatic failure | 88.84 | 63.34 | 42 | 5847 | 5647 | 2346549 |
Diffuse large B-cell lymphoma recurrent | 88.83 | 63.34 | 17 | 5872 | 81 | 2352115 |
Cellulitis | 88.54 | 63.34 | 49 | 5840 | 9152 | 2343044 |
Atelectasis | 88.32 | 63.34 | 31 | 5858 | 1934 | 2350262 |
Lung infiltration | 87.73 | 63.34 | 32 | 5857 | 2232 | 2349964 |
Pneumonia fungal | 85.38 | 63.34 | 21 | 5868 | 367 | 2351829 |
Pyomyositis | 84.62 | 63.34 | 15 | 5874 | 42 | 2352154 |
Appendicitis | 82.52 | 63.34 | 26 | 5863 | 1157 | 2351039 |
Aphasia | 81.94 | 63.34 | 38 | 5851 | 4890 | 2347306 |
Dyspnoea | 81.89 | 63.34 | 117 | 5772 | 78616 | 2273580 |
Sinusitis fungal | 81.39 | 63.34 | 16 | 5873 | 90 | 2352106 |
Stem cell transplant | 80.65 | 63.34 | 20 | 5869 | 362 | 2351834 |
Toxicity to various agents | 80.63 | 63.34 | 76 | 5813 | 32678 | 2319518 |
Pseudomonas test positive | 80.42 | 63.34 | 17 | 5872 | 144 | 2352052 |
Drug resistance | 79.58 | 63.34 | 31 | 5858 | 2593 | 2349603 |
Hodgkin's disease refractory | 78.84 | 63.34 | 12 | 5877 | 6 | 2352190 |
Ileus | 77.89 | 63.34 | 29 | 5860 | 2143 | 2350053 |
Pancreatitis | 77.66 | 63.34 | 43 | 5846 | 8036 | 2344160 |
Human bocavirus infection | 77.58 | 63.34 | 12 | 5877 | 8 | 2352188 |
Escherichia sepsis | 77.43 | 63.34 | 21 | 5868 | 547 | 2351649 |
Secondary immunodeficiency | 77.29 | 63.34 | 15 | 5874 | 78 | 2352118 |
Tachypnoea | 77.16 | 63.34 | 29 | 5860 | 2200 | 2349996 |
Systemic mycosis | 76.61 | 63.34 | 16 | 5873 | 127 | 2352069 |
Hyponatraemia | 76.60 | 63.34 | 51 | 5838 | 13274 | 2338922 |
Pericardial effusion | 76.41 | 63.34 | 34 | 5855 | 3975 | 2348221 |
Gastrointestinal haemorrhage | 74.89 | 63.34 | 49 | 5840 | 12386 | 2339810 |
Lung consolidation | 74.15 | 63.34 | 20 | 5869 | 510 | 2351686 |
Systemic candida | 73.04 | 63.34 | 18 | 5871 | 317 | 2351879 |
Pneumocystis jirovecii pneumonia | 73.01 | 63.34 | 28 | 5861 | 2245 | 2349951 |
Haemorrhage intracranial | 72.89 | 63.34 | 29 | 5860 | 2565 | 2349631 |
Haemodialysis | 71.91 | 63.34 | 27 | 5862 | 2042 | 2350154 |
Death | 71.71 | 63.34 | 112 | 5777 | 81356 | 2270840 |
Bacterial sepsis | 71.03 | 63.34 | 19 | 5870 | 469 | 2351727 |
Toxic epidermal necrolysis | 70.81 | 63.34 | 30 | 5859 | 3114 | 2349082 |
Streptococcal sepsis | 69.31 | 63.34 | 16 | 5873 | 210 | 2351986 |
General physical health deterioration | 69.18 | 63.34 | 49 | 5840 | 14090 | 2338106 |
Gamma-glutamyltransferase increased | 68.70 | 63.34 | 35 | 5854 | 5527 | 2346669 |
Hypophosphataemia | 68.38 | 63.34 | 22 | 5867 | 1048 | 2351148 |
Enteritis | 68.06 | 63.34 | 22 | 5867 | 1064 | 2351132 |
Antithrombin III | 67.93 | 63.34 | 10 | 5879 | 2 | 2352194 |
Malignant transformation | 67.85 | 63.34 | 12 | 5877 | 33 | 2352163 |
Asthenia | 67.72 | 63.34 | 82 | 5807 | 46844 | 2305352 |
C-reactive protein increased | 67.64 | 63.34 | 36 | 5853 | 6219 | 2345977 |
Peripheral motor neuropathy | 67.27 | 63.34 | 16 | 5873 | 241 | 2351955 |
Cough | 66.90 | 63.34 | 69 | 5820 | 33048 | 2319148 |
Systemic inflammatory response syndrome | 66.48 | 63.34 | 20 | 5869 | 761 | 2351435 |
Coagulopathy | 66.32 | 63.34 | 28 | 5861 | 2881 | 2349315 |
Capillary leak syndrome | 65.94 | 63.34 | 17 | 5872 | 362 | 2351834 |
Venous thrombosis | 65.50 | 63.34 | 20 | 5869 | 801 | 2351395 |
Pseudomonal sepsis | 65.29 | 63.34 | 16 | 5873 | 275 | 2351921 |
Perineal necrosis | 65.05 | 63.34 | 10 | 5879 | 6 | 2352190 |
Fusarium infection | 64.85 | 63.34 | 13 | 5876 | 82 | 2352114 |
Acute graft versus host disease in skin | 64.74 | 63.34 | 17 | 5872 | 390 | 2351806 |
Enterococcus test positive | 64.69 | 63.34 | 14 | 5875 | 134 | 2352062 |
Streptococcal bacteraemia | 64.04 | 63.34 | 14 | 5875 | 141 | 2352055 |
Cardiomyopathy | 63.93 | 63.34 | 27 | 5862 | 2780 | 2349416 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 4782.91 | 51.34 | 1194 | 6911 | 9906 | 1728770 |
Neutropenia | 1549.18 | 51.34 | 566 | 7539 | 17694 | 1720982 |
Pyrexia | 1228.63 | 51.34 | 631 | 7474 | 45769 | 1692907 |
Sepsis | 1166.59 | 51.34 | 469 | 7636 | 18969 | 1719707 |
Pancytopenia | 921.76 | 51.34 | 342 | 7763 | 11015 | 1727661 |
Thrombocytopenia | 913.67 | 51.34 | 405 | 7700 | 20844 | 1717832 |
Septic shock | 856.49 | 51.34 | 297 | 7808 | 7812 | 1730864 |
Mucosal inflammation | 824.04 | 51.34 | 246 | 7859 | 3923 | 1734753 |
Bone marrow failure | 820.33 | 51.34 | 258 | 7847 | 4942 | 1733734 |
Venoocclusive liver disease | 780.78 | 51.34 | 174 | 7931 | 759 | 1737917 |
Febrile bone marrow aplasia | 780.21 | 51.34 | 172 | 7933 | 706 | 1737970 |
Haematotoxicity | 748.93 | 51.34 | 169 | 7936 | 789 | 1737887 |
Acute myeloid leukaemia | 704.20 | 51.34 | 203 | 7902 | 2838 | 1735838 |
Product use in unapproved indication | 680.95 | 51.34 | 261 | 7844 | 9161 | 1729515 |
Multiple organ dysfunction syndrome | 614.34 | 51.34 | 241 | 7864 | 9001 | 1729675 |
Pneumonia | 603.17 | 51.34 | 399 | 7706 | 45783 | 1692893 |
Respiratory failure | 572.21 | 51.34 | 261 | 7844 | 14244 | 1724432 |
Myelodysplastic syndrome | 563.35 | 51.34 | 174 | 7931 | 3115 | 1735561 |
Off label use | 499.58 | 51.34 | 332 | 7773 | 38239 | 1700437 |
Acute kidney injury | 474.66 | 51.34 | 310 | 7795 | 34634 | 1704042 |
Hypotension | 467.14 | 51.34 | 289 | 7816 | 29365 | 1709311 |
Colitis | 447.54 | 51.34 | 155 | 7950 | 4025 | 1734651 |
Bronchopulmonary aspergillosis | 445.87 | 51.34 | 123 | 7982 | 1443 | 1737233 |
Hyperbilirubinaemia | 399.85 | 51.34 | 123 | 7982 | 2164 | 1736512 |
Fungal infection | 375.80 | 51.34 | 117 | 7988 | 2145 | 1736531 |
Aspergillus infection | 364.00 | 51.34 | 102 | 8003 | 1271 | 1737405 |
Platelet count decreased | 346.14 | 51.34 | 194 | 7911 | 16329 | 1722347 |
Tumour lysis syndrome | 343.81 | 51.34 | 103 | 8002 | 1648 | 1737028 |
Bacteraemia | 336.59 | 51.34 | 103 | 8002 | 1777 | 1736899 |
Leukoencephalopathy | 328.48 | 51.34 | 84 | 8021 | 716 | 1737960 |
Anaemia | 324.53 | 51.34 | 230 | 7875 | 29227 | 1709449 |
Neutropenic sepsis | 306.94 | 51.34 | 91 | 8014 | 1401 | 1737275 |
Stomatitis | 299.88 | 51.34 | 124 | 7981 | 5280 | 1733396 |
Blood bilirubin increased | 299.62 | 51.34 | 129 | 7976 | 6081 | 1732595 |
Aplasia | 299.48 | 51.34 | 70 | 8035 | 390 | 1738286 |
Hypoxia | 298.02 | 51.34 | 127 | 7978 | 5836 | 1732840 |
Alanine aminotransferase increased | 295.18 | 51.34 | 158 | 7947 | 12120 | 1726556 |
Infection | 294.19 | 51.34 | 158 | 7947 | 12202 | 1726474 |
Neutropenic colitis | 293.15 | 51.34 | 63 | 8042 | 221 | 1738455 |
Blood culture positive | 291.42 | 51.34 | 76 | 8029 | 705 | 1737971 |
Hypertriglyceridaemia | 280.68 | 51.34 | 81 | 8024 | 1128 | 1737548 |
Myelopathy | 280.40 | 51.34 | 63 | 8042 | 285 | 1738391 |
Acute lymphocytic leukaemia recurrent | 278.14 | 51.34 | 61 | 8044 | 241 | 1738435 |
Pleural effusion | 275.54 | 51.34 | 146 | 7959 | 10964 | 1727712 |
Neoplasm progression | 269.67 | 51.34 | 100 | 8005 | 3167 | 1735509 |
Acute myeloid leukaemia recurrent | 268.01 | 51.34 | 58 | 8047 | 212 | 1738464 |
Abdominal pain | 262.57 | 51.34 | 179 | 7926 | 21311 | 1717365 |
Second primary malignancy | 259.47 | 51.34 | 74 | 8031 | 985 | 1737691 |
Hypofibrinogenaemia | 257.18 | 51.34 | 54 | 8051 | 164 | 1738512 |
Cytomegalovirus infection | 250.45 | 51.34 | 95 | 8010 | 3206 | 1735470 |
Vomiting | 248.43 | 51.34 | 219 | 7886 | 38096 | 1700580 |
Staphylococcal infection | 237.58 | 51.34 | 101 | 8004 | 4606 | 1734070 |
Renal failure | 233.27 | 51.34 | 162 | 7943 | 19855 | 1718821 |
Diarrhoea | 228.92 | 51.34 | 244 | 7861 | 53608 | 1685068 |
Neutrophil count decreased | 228.23 | 51.34 | 106 | 7999 | 5975 | 1732701 |
White blood cell count decreased | 223.60 | 51.34 | 135 | 7970 | 13014 | 1725662 |
Device related infection | 222.30 | 51.34 | 79 | 8026 | 2207 | 1736469 |
Posterior reversible encephalopathy syndrome | 218.71 | 51.34 | 70 | 8035 | 1405 | 1737271 |
Tachycardia | 210.44 | 51.34 | 128 | 7977 | 12500 | 1726176 |
Nausea | 206.97 | 51.34 | 226 | 7879 | 50970 | 1687706 |
Venoocclusive disease | 203.87 | 51.34 | 49 | 8056 | 313 | 1738363 |
Disease progression | 201.70 | 51.34 | 140 | 7965 | 17123 | 1721553 |
Hepatotoxicity | 199.26 | 51.34 | 79 | 8026 | 3005 | 1735671 |
Malignant neoplasm progression | 196.98 | 51.34 | 128 | 7977 | 14030 | 1724646 |
Cytopenia | 192.05 | 51.34 | 57 | 8048 | 879 | 1737797 |
Mucormycosis | 191.09 | 51.34 | 54 | 8051 | 693 | 1737983 |
Aspartate aminotransferase increased | 189.43 | 51.34 | 113 | 7992 | 10643 | 1728033 |
Leukopenia | 189.29 | 51.34 | 104 | 8001 | 8376 | 1730300 |
Acute respiratory distress syndrome | 185.14 | 51.34 | 78 | 8027 | 3473 | 1735203 |
Cytomegalovirus chorioretinitis | 184.73 | 51.34 | 46 | 8059 | 347 | 1738329 |
Candida infection | 180.30 | 51.34 | 65 | 8040 | 1893 | 1736783 |
Drug ineffective | 171.50 | 51.34 | 229 | 7876 | 63572 | 1675104 |
Escherichia sepsis | 166.38 | 51.34 | 47 | 8058 | 602 | 1738074 |
Respiratory distress | 166.24 | 51.34 | 81 | 8024 | 5076 | 1733600 |
Leukaemia recurrent | 165.94 | 51.34 | 40 | 8065 | 259 | 1738417 |
Pulmonary oedema | 158.69 | 51.34 | 85 | 8020 | 6501 | 1732175 |
Clostridium difficile colitis | 158.06 | 51.34 | 56 | 8049 | 1548 | 1737128 |
Neurotoxicity | 152.54 | 51.34 | 58 | 8047 | 1966 | 1736710 |
Nervous system disorder | 152.02 | 51.34 | 61 | 8044 | 2393 | 1736283 |
Haemophagocytic lymphohistiocytosis | 151.60 | 51.34 | 53 | 8052 | 1407 | 1737269 |
Seizure | 146.52 | 51.34 | 124 | 7981 | 20317 | 1718359 |
Neuropathy peripheral | 144.36 | 51.34 | 90 | 8015 | 9163 | 1729513 |
Osteonecrosis | 142.17 | 51.34 | 67 | 8038 | 3895 | 1734781 |
Acute lymphocytic leukaemia | 141.04 | 51.34 | 40 | 8065 | 520 | 1738156 |
Enterococcal infection | 138.64 | 51.34 | 44 | 8061 | 857 | 1737819 |
Bacterial infection | 137.93 | 51.34 | 53 | 8052 | 1849 | 1736827 |
Staphylococcal bacteraemia | 135.85 | 51.34 | 42 | 8063 | 748 | 1737928 |
Malignant transformation | 133.92 | 51.34 | 26 | 8079 | 45 | 1738631 |
Graft versus host disease | 133.44 | 51.34 | 49 | 8056 | 1504 | 1737172 |
Pulmonary haemorrhage | 132.77 | 51.34 | 50 | 8055 | 1649 | 1737027 |
Encephalopathy | 131.78 | 51.34 | 66 | 8039 | 4386 | 1734290 |
Bacterial sepsis | 130.32 | 51.34 | 39 | 8066 | 619 | 1738057 |
Gamma-glutamyltransferase increased | 129.00 | 51.34 | 68 | 8037 | 5030 | 1733646 |
Hypokalaemia | 128.08 | 51.34 | 73 | 8032 | 6301 | 1732375 |
Pneumonia fungal | 127.86 | 51.34 | 36 | 8069 | 455 | 1738221 |
Escherichia infection | 126.40 | 51.34 | 42 | 8063 | 951 | 1737725 |
Diffuse large B-cell lymphoma | 125.00 | 51.34 | 43 | 8062 | 1086 | 1737590 |
Chills | 122.94 | 51.34 | 89 | 8016 | 11598 | 1727078 |
Disseminated intravascular coagulation | 120.15 | 51.34 | 58 | 8047 | 3556 | 1735120 |
Transaminases increased | 118.67 | 51.34 | 59 | 8046 | 3858 | 1734818 |
Chloroma | 118.51 | 51.34 | 25 | 8080 | 78 | 1738598 |
Disease recurrence | 115.76 | 51.34 | 51 | 8054 | 2531 | 1736145 |
Systemic candida | 114.27 | 51.34 | 31 | 8074 | 338 | 1738338 |
Diffuse large B-cell lymphoma recurrent | 112.33 | 51.34 | 25 | 8080 | 107 | 1738569 |
Toxicity to various agents | 109.28 | 51.34 | 124 | 7981 | 29017 | 1709659 |
Ascites | 106.93 | 51.34 | 62 | 8043 | 5524 | 1733152 |
Atrial fibrillation | 106.81 | 51.34 | 91 | 8014 | 15020 | 1723656 |
Hepatic failure | 106.36 | 51.34 | 63 | 8042 | 5840 | 1732836 |
Atelectasis | 105.84 | 51.34 | 44 | 8061 | 1890 | 1736786 |
Parainfluenzae virus infection | 105.23 | 51.34 | 26 | 8079 | 189 | 1738487 |
Lung infiltration | 104.45 | 51.34 | 45 | 8060 | 2114 | 1736562 |
Agranulocytosis | 102.84 | 51.34 | 52 | 8053 | 3524 | 1735152 |
Staphylococcal sepsis | 102.77 | 51.34 | 38 | 8067 | 1189 | 1737487 |
Clostridium difficile infection | 102.48 | 51.34 | 42 | 8063 | 1739 | 1736937 |
Pancreatitis | 102.30 | 51.34 | 66 | 8039 | 7121 | 1731555 |
Mental status changes | 102.11 | 51.34 | 62 | 8043 | 6013 | 1732663 |
Oedema | 101.85 | 51.34 | 65 | 8040 | 6883 | 1731793 |
Headache | 100.64 | 51.34 | 129 | 7976 | 34247 | 1704429 |
Coagulopathy | 99.65 | 51.34 | 47 | 8058 | 2734 | 1735942 |
Escherichia bacteraemia | 99.47 | 51.34 | 27 | 8078 | 295 | 1738381 |
Viral haemorrhagic cystitis | 98.95 | 51.34 | 21 | 8084 | 68 | 1738608 |
Epstein-Barr virus infection | 98.50 | 51.34 | 36 | 8069 | 1089 | 1737587 |
Neoplasm recurrence | 97.00 | 51.34 | 28 | 8077 | 389 | 1738287 |
Muscular weakness | 96.42 | 51.34 | 73 | 8032 | 10176 | 1728500 |
Hypertension | 96.33 | 51.34 | 96 | 8009 | 19352 | 1719324 |
Cystitis haemorrhagic | 96.19 | 51.34 | 31 | 8074 | 635 | 1738041 |
Klebsiella infection | 93.95 | 51.34 | 32 | 8073 | 783 | 1737893 |
Cerebral haemorrhage | 92.69 | 51.34 | 59 | 8046 | 6218 | 1732458 |
Acute promyelocytic leukaemia | 91.03 | 51.34 | 22 | 8083 | 144 | 1738532 |
Systemic mycosis | 89.88 | 51.34 | 22 | 8083 | 153 | 1738523 |
Pneumonia cytomegaloviral | 89.81 | 51.34 | 26 | 8079 | 365 | 1738311 |
Cardiac failure | 89.24 | 51.34 | 76 | 8029 | 12526 | 1726150 |
Cytogenetic abnormality | 88.44 | 51.34 | 23 | 8082 | 210 | 1738466 |
Condition aggravated | 87.84 | 51.34 | 95 | 8010 | 21055 | 1717621 |
Sinusitis | 86.98 | 51.34 | 53 | 8052 | 5170 | 1733506 |
Dyspnoea | 86.86 | 51.34 | 150 | 7955 | 51909 | 1686767 |
Cardiotoxicity | 85.72 | 51.34 | 30 | 8075 | 798 | 1737878 |
Stem cell transplant | 85.26 | 51.34 | 26 | 8079 | 441 | 1738235 |
Cholestasis | 84.58 | 51.34 | 46 | 8059 | 3619 | 1735057 |
Fluid overload | 83.82 | 51.34 | 38 | 8067 | 2017 | 1736659 |
Cellulitis | 81.36 | 51.34 | 55 | 8050 | 6413 | 1732263 |
Therapy non-responder | 80.54 | 51.34 | 54 | 8051 | 6212 | 1732464 |
Cytokine release syndrome | 80.51 | 51.34 | 26 | 8079 | 536 | 1738140 |
Pericardial effusion | 79.48 | 51.34 | 43 | 8062 | 3347 | 1735329 |
Hypoalbuminaemia | 79.15 | 51.34 | 33 | 8072 | 1427 | 1737249 |
Tachypnoea | 78.83 | 51.34 | 38 | 8067 | 2320 | 1736356 |
Blood creatinine increased | 78.72 | 51.34 | 74 | 8031 | 13872 | 1724804 |
Retinal haemorrhage | 78.13 | 51.34 | 31 | 8074 | 1178 | 1737498 |
Lymphopenia | 77.91 | 51.34 | 36 | 8069 | 1997 | 1736679 |
Hepatomegaly | 77.83 | 51.34 | 34 | 8071 | 1651 | 1737025 |
Ejection fraction decreased | 77.54 | 51.34 | 37 | 8068 | 2208 | 1736468 |
Decreased appetite | 76.82 | 51.34 | 94 | 8011 | 23777 | 1714899 |
Stenotrophomonas infection | 76.67 | 51.34 | 20 | 8085 | 185 | 1738491 |
Sinus tachycardia | 76.26 | 51.34 | 38 | 8067 | 2494 | 1736182 |
Cough | 75.81 | 51.34 | 84 | 8021 | 19113 | 1719563 |
Drug resistance | 75.81 | 51.34 | 41 | 8064 | 3189 | 1735487 |
Blindness | 75.57 | 51.34 | 39 | 8066 | 2757 | 1735919 |
Dysphagia | 75.42 | 51.34 | 63 | 8042 | 10105 | 1728571 |
Fusarium infection | 74.85 | 51.34 | 18 | 8087 | 115 | 1738561 |
Epistaxis | 73.35 | 51.34 | 57 | 8048 | 8249 | 1730427 |
Haemoglobin decreased | 73.00 | 51.34 | 78 | 8027 | 17036 | 1721640 |
Palmar-plantar erythrodysaesthesia syndrome | 72.65 | 51.34 | 41 | 8064 | 3466 | 1735210 |
Progressive multifocal leukoencephalopathy | 72.24 | 51.34 | 32 | 8073 | 1607 | 1737069 |
Pneumocystis jirovecii pneumonia | 71.44 | 51.34 | 36 | 8069 | 2420 | 1736256 |
Glioma | 70.88 | 51.34 | 16 | 8089 | 74 | 1738602 |
Metabolic acidosis | 70.49 | 51.34 | 47 | 8058 | 5355 | 1733321 |
Cardio-respiratory arrest | 69.79 | 51.34 | 58 | 8047 | 9235 | 1729441 |
Encephalitis | 69.45 | 51.34 | 28 | 8077 | 1110 | 1737566 |
Pseudomonas test positive | 69.35 | 51.34 | 17 | 8088 | 119 | 1738557 |
General physical health deterioration | 69.08 | 51.34 | 67 | 8038 | 13051 | 1725625 |
Autoimmune lymphoproliferative syndrome | 68.98 | 51.34 | 12 | 8093 | 6 | 1738670 |
Shock | 68.70 | 51.34 | 42 | 8063 | 4119 | 1734557 |
Capillary leak syndrome | 68.61 | 51.34 | 20 | 8085 | 288 | 1738388 |
Burkitt's lymphoma | 67.70 | 51.34 | 17 | 8088 | 133 | 1738543 |
Hyperglycaemia | 67.54 | 51.34 | 45 | 8060 | 5120 | 1733556 |
Facial paralysis | 67.46 | 51.34 | 32 | 8073 | 1884 | 1736792 |
Confusional state | 67.16 | 51.34 | 83 | 8022 | 21195 | 1717481 |
Blood HIV RNULL increased | 66.44 | 51.34 | 18 | 8087 | 195 | 1738481 |
Post transplant lymphoproliferative disorder | 65.65 | 51.34 | 24 | 8081 | 726 | 1737950 |
Treatment failure | 64.04 | 51.34 | 41 | 8064 | 4360 | 1734316 |
Gastrointestinal wall thickening | 62.86 | 51.34 | 16 | 8089 | 133 | 1738543 |
Systemic inflammatory response syndrome | 62.84 | 51.34 | 24 | 8081 | 822 | 1737854 |
Enterobacter infection | 62.08 | 51.34 | 18 | 8087 | 254 | 1738422 |
Haemodynamic instability | 61.82 | 51.34 | 27 | 8078 | 1310 | 1737366 |
Asthenia | 61.80 | 51.34 | 103 | 8002 | 34567 | 1704109 |
Cardiac arrest | 61.66 | 51.34 | 69 | 8036 | 15861 | 1722815 |
Enterocolitis | 61.37 | 51.34 | 24 | 8081 | 877 | 1737799 |
Hepatosplenic candidiasis | 61.36 | 51.34 | 12 | 8093 | 22 | 1738654 |
Paraplegia | 61.33 | 51.34 | 21 | 8084 | 522 | 1738154 |
Hyponatraemia | 61.08 | 51.34 | 53 | 8052 | 8947 | 1729729 |
Left ventricular dysfunction | 61.06 | 51.34 | 26 | 8079 | 1185 | 1737491 |
Dialysis | 60.58 | 51.34 | 32 | 8073 | 2372 | 1736304 |
Hepatitis B | 60.57 | 51.34 | 27 | 8078 | 1376 | 1737300 |
Skin toxicity | 59.31 | 51.34 | 21 | 8084 | 578 | 1738098 |
Lung consolidation | 58.94 | 51.34 | 21 | 8084 | 589 | 1738087 |
Intracranial pressure increased | 58.23 | 51.34 | 22 | 8083 | 731 | 1737945 |
Paraesthesia | 58.07 | 51.34 | 55 | 8050 | 10396 | 1728280 |
Hypogammaglobulinaemia | 57.99 | 51.34 | 21 | 8084 | 618 | 1738058 |
Respiratory tract infection fungal | 57.24 | 51.34 | 14 | 8091 | 97 | 1738579 |
Pneumonia klebsiella | 57.01 | 51.34 | 18 | 8087 | 344 | 1738332 |
Oxygen saturation decreased | 56.84 | 51.34 | 42 | 8063 | 5633 | 1733043 |
Adenovirus infection | 56.67 | 51.34 | 19 | 8086 | 442 | 1738234 |
Dehydration | 55.89 | 51.34 | 69 | 8036 | 17589 | 1721087 |
Acute graft versus host disease | 55.71 | 51.34 | 22 | 8083 | 825 | 1737851 |
Klebsiella sepsis | 55.70 | 51.34 | 16 | 8089 | 218 | 1738458 |
Dysarthria | 55.11 | 51.34 | 40 | 8065 | 5219 | 1733457 |
Ileus | 54.48 | 51.34 | 30 | 8075 | 2416 | 1736260 |
Intussusception | 54.41 | 51.34 | 14 | 8091 | 122 | 1738554 |
Geotrichum infection | 54.36 | 51.34 | 11 | 8094 | 26 | 1738650 |
Guillain-Barre syndrome | 54.11 | 51.34 | 22 | 8083 | 891 | 1737785 |
Basal cell carcinoma | 54.06 | 51.34 | 30 | 8075 | 2453 | 1736223 |
Therapeutic product effect incomplete | 53.85 | 51.34 | 40 | 8065 | 5408 | 1733268 |
Haemorrhage intracranial | 53.58 | 51.34 | 33 | 8072 | 3277 | 1735399 |
Appendicitis | 52.48 | 51.34 | 23 | 8082 | 1125 | 1737551 |
Trichosporon infection | 51.96 | 51.34 | 13 | 8092 | 100 | 1738576 |
Brain oedema | 51.87 | 51.34 | 28 | 8077 | 2168 | 1736508 |
Pseudomonal sepsis | 51.86 | 51.34 | 17 | 8088 | 368 | 1738308 |
Hepatocellular injury | 51.76 | 51.34 | 32 | 8073 | 3199 | 1735477 |
Skin lesion | 51.63 | 51.34 | 31 | 8074 | 2941 | 1735735 |
Hemiparesis | 51.37 | 51.34 | 30 | 8075 | 2704 | 1735972 |
Source | Code | Description |
---|---|---|
ATC | L01BC01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Pyrimidine analogues |
ATC | L01XY01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Combinations of antineoplastic agents |
FDA MoA | N0000000233 | Nucleic Acid Synthesis Inhibitors |
FDA EPC | N0000175595 | Nucleoside Metabolic Inhibitor |
CHEBI has role | CHEBI:35610 | antineoplastic agent |
CHEBI has role | CHEBI:35705 | immunosuppressive agent |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000964 | Antimetabolites, Antineoplastic |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
MeSH PA | D009676 | Noxae |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute lymphoid leukemia | indication | 91857003 | DOID:9952 |
Acute myeloid leukemia, disease | indication | 91861009 | |
Acute promyelocytic leukemia, FAB M3 | indication | 110004001 | |
Lymphomatous meningitis | indication | 426128009 | |
Meningeal Leukemia | indication | ||
Allogeneic bone marrow transplantation | off-label use | 58390007 | |
Chronic myeloid leukemia | off-label use | 92818009 | DOID:8552 |
Diffuse non-Hodgkin's lymphoma, large cell | off-label use | 109969005 | |
Myelodysplastic syndrome | off-label use | 109995007 | |
Burkitt's lymphoma | off-label use | 118617000 | |
Progressive Diffuse Large B-Cell Lymphoma | off-label use | ||
Adjunct for CNS Disease Prevention in Non-Hodgkin's Lymphoma | off-label use | ||
Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
Mycosis | contraindication | 3218000 | DOID:1564 |
Pulmonary edema | contraindication | 19242006 | DOID:11396 |
Viral disease | contraindication | 34014006 | DOID:934 |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Stomatitis | contraindication | 61170000 | DOID:9637 |
Diarrhea | contraindication | 62315008 | |
Adult respiratory distress syndrome | contraindication | 67782005 | DOID:11394 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Cardiomyopathy | contraindication | 85898001 | DOID:0050700 |
Bacterial infectious disease | contraindication | 87628006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Infectious disease of central nervous system | contraindication | 128117002 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Peripheral nerve disease | contraindication | 302226006 | |
Bone marrow depression | contraindication | 307762000 | |
Coma | contraindication | 371632003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Acute cerebellar syndrome | contraindication | 417017003 | |
Granulocytopenic disorder | contraindication | 417672002 | |
Vomiting | contraindication | 422400008 | |
Protozoal Infection | contraindication | ||
Intestinal Ischemic Necrosis | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.91 | acidic |
pKa2 | 12.58 | acidic |
pKa3 | 12.97 | acidic |
pKa4 | 4.04 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 8431806 | April 22, 2025 | FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 7850990 | Jan. 23, 2027 | FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 8022279 | Sept. 14, 2027 | FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 8092828 | April 1, 2029 | FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 10166184 | Oct. 15, 2032 | METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 10028912 | Sept. 29, 2034 | METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | 10028912 | Sept. 29, 2034 | METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG | VYXEOS | CELATOR PHARMS | N209401 | Aug. 3, 2017 | RX | POWDER | INTRAVENOUS | Aug. 3, 2020 | NEW PRODUCT |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA polymerase (alpha/delta/epsilon) | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Prostatic acid phosphatase | Enzyme | GI50 | 7 | WOMBAT-PK | |||||
DNA polymerase beta | Enzyme | WOMBAT-PK | |||||||
Enoyl-[acyl-carrier-protein] reductase [NADH] | Enzyme | IC50 | 4.23 | CHEMBL |
ID | Source |
---|---|
D003561 | MESH_DESCRIPTOR_UI |
4018080 | VUID |
N0000146419 | NUI |
C0010711 | UMLSCUI |
D00168 | KEGG_DRUG |
04079A1RDZ | UNII |
1709 | INN_ID |
69-74-9 | SECONDARY_CAS_RN |
89265009 | SNOMEDCT_US |
4018080 | VANDF |
002649 | NDDF |
372 | MMSL |
3041 | RXNORM |
387511003 | SNOMEDCT_US |
4526 | MMSL |
d00201 | MMSL |
6253 | PUBCHEM_CID |
CHEBI:28680 | CHEBI |
CHEMBL803 | ChEMBL_ID |
DB00987 | DRUGBANK_ID |
CHEMBL596186 | ChEMBL_ID |
AR3 | PDB_CHEM_ID |
4827 | IUPHAR_LIGAND_ID |
CHEMBL1256472 | ChEMBL_ID |
CHEMBL2092816 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
CYTARABINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-303 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 14 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-304 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 14 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-305 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 14 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61703-319 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 16 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-120 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 14 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-452 | INJECTION | 2 g | INTRATHECAL | ANDA | 14 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-454 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 14 sections |
cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-455 | INJECTION | 100 mg | INTRAVENOUS | ANDA | 14 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68083-337 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | ANDA | 13 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68083-343 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 12 sections |
VYXEOS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68727-745 | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION | 100 mg | INTRAVENOUS | NDA | 17 sections |
Cytarabine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-109 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | ANDA | 14 sections |